During this health emergency produced by the pandemic caused by SARS CoV-2 infection (COVID-19), the world is facing a challenging array in patient care, mainly due to a lack of robust scientificevidence that allows the presentation of conclusive results to define an adequate clinical and pharmacological treatment based on clinical evidence.
Furthermore, as it is a new virus, it is still unknown which systems it modifies or alters and how these alterations affect the transit of drugs in the body (for example, metabolizing enzymes, modification of excretion or imbalances in coagulation). Thus, on the one hand, drugs with little experience of use are being used, but, on the other hand, common drugs are also being used in an unresearched and unapproved indication, and therefore may have different or unknown adverse effects.
Guide_For_the_development_of_pharmacovigilance_in_the_context_SARS_CoV_Covid-19